Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-137

Totally agree.

Some figures from the ann:
'' vehicle responses in the USA were unexpectedly high...inflammatory lesion reduction (45.9% reduction in the USA)''

Also figures of some currently available acne treatments (from previous ann)

BTX1503 itself achieved a 47% reduction in inflammatory lesions at 4 weeks ...

Looks like ~40% is a satisfactory therapeutic effect.

Now tell me how can a vehicle/placebo have achieved the same effect?

Human error must be the only explanation...

However, I doubt how many holders will read and analyse the whole ann. ''The primary endpoint did not achieve statistical significance'' sounds horrific enough